Drug Profile
Research programme: diabetes therapeutics - CureDM
Alternative Names: CDM 1101; CDM 1102; CDM 1103; Proisletide acetateLatest Information Update: 05 Apr 2018
Price :
$50
*
At a glance
- Originator CureDM
- Class Peptide fragments
- Mechanism of Action Cell differentiation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (Parenteral)
- 06 Aug 2007 CureDM is seeking development and commercialisation partners (www.curedm.com)